# Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

> **NCT02584933** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 233 (actual)

## Conditions studied

- ALK Positive Malignancies

## Interventions

- **DRUG:** ceritinib

## Key facts

- **NCT ID:** NCT02584933
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-12-11
- **Primary completion:** 2027-06-09
- **Final completion:** 2027-06-09
- **Target enrollment:** 233 (ACTUAL)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02584933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02584933, "Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02584933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*